Literature DB >> 33613940

Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease.

Andrew J Fowell1, Kirsty Fancey1, Karen Gamble1, Kelly Bicknell2, Joanna K Dowman1, Paul Howden3, Richard J Aspinall1.   

Abstract

OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) affects approximately one in four adults of the general population, with an important minority of cases at high risk of developing cirrhosis. We evaluated the utility of a primary care NAFLD pathway incorporating a specialist nurse-led NAFLD clinic and a two-step testing approach for advanced liver fibrosis. DESIGN/
METHOD: We performed a retrospective evaluation of prospectively collected demographic and clinical data on all patients diagnosed with NAFLD and intermediate NAFLD fibrosis score seen in our nurse-led NAFLD clinic between 1 May 2014 and 30 April 2017. Patients were assessed using a specific clerking pro forma and transient elastography (TE). Discharge to primary care with lifestyle advice was considered where TE<7.9 kPa.
RESULTS: 904 patients were identified, 114 (12.6%) of whom did not meet NAFLD criteria. Among the NAFLD population (n=790 (87.4%)), TE<7.9 kPa was present in 558 patients (70.6%), 519 of whom were discharged to primary care. Selected patients were followed up in secondary care despite TE<7.9 kPa or discharged with TE≥7.9 kPa. TE was unreliable in 22 patients (2.7%). Overall, 559 (70.8%) of patients with confirmed NAFLD were discharged from the nurse-led clinic. Introduction of the new pathway was associated with increased screening for hepatitis B and C viruses in primary care, and 17 new cases of alpha-1-antitrypsin deficiency were identified.
CONCLUSION: An integrated primary/secondary care NAFLD pathway, including a specialist nurse-led clinic may be a useful way of managing increasing demand on secondary care hepatology services. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chronic liver disease; fatty liver; fibrosis; non-alcoholic steatohepatitis; primary care

Year:  2020        PMID: 33613940      PMCID: PMC7873539          DOI: 10.1136/flgastro-2019-101304

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  19 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

2.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

3.  Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease.

Authors:  S A Townsend; R G Edgar; P R Ellis; D Kantas; P N Newsome; A M Turner
Journal:  Aliment Pharmacol Ther       Date:  2018-02-15       Impact factor: 8.171

Review 4.  Alpha1-antitrypsin deficiency.

Authors:  James K Stoller; Loutfi S Aboussouan
Journal:  Lancet       Date:  2005 Jun 25-Jul 1       Impact factor: 79.321

5.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

6.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

7.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.

Authors:  Vincent Wai-Sun Wong; Julien Vergniol; Grace Lai-Hung Wong; Juliette Foucher; Henry Lik-Yuen Chan; Brigitte Le Bail; Paul Cheung-Lung Choi; Mathurin Kowo; Anthony Wing-Hung Chan; Wassil Merrouche; Joseph Jao-Yiu Sung; Victor de Lédinghen
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

8.  Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.

Authors:  Elliot B Tapper; M G Myriam Hunink; Nezam H Afdhal; Michelle Lai; Neil Sengupta
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

9.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.

Authors:  Stuart McPherson; Tim Hardy; Jean-Francois Dufour; Salvatore Petta; Manuel Romero-Gomez; Mike Allison; Claudia P Oliveira; Sven Francque; Luc Van Gaal; Jörn M Schattenberg; Dina Tiniakos; Alastair Burt; Elisabetta Bugianesi; Vlad Ratziu; Christopher P Day; Quentin M Anstee
Journal:  Am J Gastroenterol       Date:  2016-10-11       Impact factor: 10.864

Review 10.  Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging.

Authors:  Jessica K Dyson; Quentin M Anstee; Stuart McPherson
Journal:  Frontline Gastroenterol       Date:  2013-12-24
View more
  2 in total

Review 1.  Identification of liver disease: why and how.

Authors:  Iain Macpherson; Kushala W M Abeysekera; Rebecca Harris; Dina Mansour; Stuart McPherson; Ian Rowe; William Rosenberg; John F Dillon; Andrew Yeoman
Journal:  Frontline Gastroenterol       Date:  2022-01-24

Review 2.  New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.

Authors:  Roger Williams; Charles Alessi; Graeme Alexander; Michael Allison; Richard Aspinall; Rachel L Batterham; Neeraj Bhala; Natalie Day; Anil Dhawan; Colin Drummond; James Ferguson; Graham Foster; Ian Gilmore; Raphael Goldacre; Harriet Gordon; Clive Henn; Deirdre Kelly; Alastair MacGilchrist; Roger McCorry; Neil McDougall; Zulfiquar Mirza; Kieran Moriarty; Philip Newsome; Richard Pinder; Stephen Roberts; Harry Rutter; Stephen Ryder; Marianne Samyn; Katherine Severi; Nick Sheron; Douglas Thorburn; Julia Verne; John Williams; Andrew Yeoman
Journal:  Lancet       Date:  2021-03-11       Impact factor: 202.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.